Epoch Investment Partners Inc. Has $84.08 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Epoch Investment Partners Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 575,286 shares of the company’s stock after purchasing an additional 11,630 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Johnson & Johnson were worth $84,084,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Mount Yale Investment Advisors LLC increased its position in Johnson & Johnson by 0.4% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 22,147 shares of the company’s stock worth $3,237,000 after purchasing an additional 96 shares in the last quarter. Frank Rimerman Advisors LLC increased its position in Johnson & Johnson by 1,811.6% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 31,541 shares of the company’s stock worth $4,610,000 after purchasing an additional 29,891 shares in the last quarter. Prospector Partners LLC increased its position in Johnson & Johnson by 1.0% during the 2nd quarter. Prospector Partners LLC now owns 66,134 shares of the company’s stock worth $9,666,000 after purchasing an additional 660 shares in the last quarter. ProShare Advisors LLC increased its position in Johnson & Johnson by 9.8% during the 2nd quarter. ProShare Advisors LLC now owns 1,651,733 shares of the company’s stock worth $241,417,000 after purchasing an additional 147,609 shares in the last quarter. Finally, Kowal Investment Group LLC increased its position in Johnson & Johnson by 1.2% in the 2nd quarter. Kowal Investment Group LLC now owns 9,888 shares of the company’s stock valued at $1,445,000 after acquiring an additional 121 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Down 0.4 %

Shares of NYSE JNJ opened at $164.16 on Friday. The firm has a market cap of $395.08 billion, a PE ratio of 10.23, a P/E/G ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company’s fifty day simple moving average is $161.30 and its 200 day simple moving average is $154.16. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period last year, the firm earned $2.80 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a $1.24 dividend. The ex-dividend date was Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. TD Securities decreased their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. The Goldman Sachs Group decreased their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, September 16th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.